Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. freshman Good
|
New words:
abroad, aggressive, API, cancelled, carboplatin, cisplatin, constituting, deadly, Eli, endpoint, evidence, fractional, Genentech, GlaxoSmithKline, goal, half, inaccuracy, Ingredient, intangible, lead, left, Lilly, Lynch, member, Merrill, modification, nonpayment, Onyx, Pacific, par, Pfizer, pharmaceutical, pivotal, PM, preceding, prepayment, radiation, repurchase, respond, Silicon, Squibb, sublicense, supplier, unrestricted, Valley, Vion
Filing tables
PARD similar filings
Filing view
External links